Bard1 Life Sciences Share Price and Company Fundamentals



Price
$1.325
Change
-0.015 (-1.119%)
52 week
0.57 - 5.6

Last traded: Last Friday at 6:10 AM

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Key Metrics

PE ratio

-

PB ratio

3.81

Dividend yield

Beta

-0.76

Market cap

$121.81M

Enterprise value

$102.34M

Company profile

Primary activitiesDeveloping and commercialising cancer diagnostic products.
Industry / SectorDiagnostics & Research / Healthcare
Full time employees15
Websitehttp://www.bard1.com
Mailing address23 Normanby Road Notting Hill VIC 3168 Australia
Phone / Fax61 3 9548 7586 /
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Bard1 Life Sciences does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Bard1 Life Sciences.

NameTitleAgeTotal Pay
Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.Chief Exec. Officer417.64k
Mr. Peter Lynton Gunzburg B Comm, ASIAManaging Director6882.12k
Mr. Tony Di Pietro AGIA, C.A., M.A.I.C.D., B.Com, CPACFO & Joint Company Sec.
Mr. Carl S. Stubbings BScChief Operations Officer
Dr. Peter William French B.Sc., FRSM, M.B.A., M.Sc., MBA, Ph.D.Chief Scientific Officer
Ms. Pauline Anne CollinsonJoint Company Sec.64

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-1,413.66%

Return on assets

-20.52%

Return on equity

-72.08%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Bard1 Life Sciences is 121.81M and its enterprise value is 102.34M. The enterprise value to revenue ratio of BD1 is 218.63.

Companies similar to Bard1 Life Sciences (BD1)

Bard1 Life Sciences (ASX:BD1) Frequently Asked Questions

1. What is Bard1 Life Sciences's Stock Symbol?

Bard1 Life Sciences trades on ASX under the ticker symbol "BD1".

2. What is Bard1 Life Sciences's stock price today?

One share of BD1 stock can currently be purchased for approximately $1.325.

3. How can I contact Bard1 Life Sciences?

Bard1 Life Sciences's mailing address is 23 Normanby Road Notting Hill VIC 3168 Australia. The company can be reached via phone at 61 3 9548 7586.

4. What is Bard1 Life Sciences's official website?

The official website of Bard1 Life Sciences is http://www.bard1.com.

5. Which share registry manages Bard1 Life Sciences's stock?

Bard1 Life Sciences's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.